Nogo-A has been previously identified as a prognostic marker and therapeutic target in ALS due to its substantial expression in motor neuron disease and destabilizing effect on neuromuscular junctions [102,103]. This evidence concerns the gene RTN4 and amyotrophic lateral sclerosis.